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Background: Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms
of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Since ATO induces
apoptosis in in vitro models, we compared the expression of 93 apoptotic genes in patients’ bone marrow before and
after ATO treatment. For this analysis, we selected 12 patients affected by MDS who received ATO in combination with
Ascorbic Acid in the context of the Italian clinical trial NCT00803530, EudracT Number 2005-001321-28.
Methods: Real-time PCR quantitative assays for genes involved in apoptosis were performed using TaqManW Assays in
384-Well Microfluidic Cards “TaqManW Human Apoptosis Array”.
Quantitative RT-PCR for expression of EVI1 and WT1 genes was also performed. Gene expression values (Ct) were
normalized to the median expression of 3 housekeeping genes present in the card (18S, ACTB and GAPDH).
Results: ATO treatment induced up-regulation of some pro-apoptotic genes, such as HRK, BAK1, CASPASE-5, BAD,
TNFRSF1A, and BCL2L14 and down-regulation of ICEBERG. In the majority of cases with stable disease, apoptotic gene
expression profile did not change, whereas in cases with advanced MDS more frequently pro-apoptotic genes were
up-regulated. Two patients achieved a major response: in the patient with refractory anemia the treatment
down-regulated 69% of the pro-apoptotic genes, whereas 91% of the pro-apoptotic genes were up-regulated in the
patient affected by refractory anemia with excess of blasts-1. Responsive patients showed a higher induction of BAD
than those with stable disease. Finally, WT1 gene expression was down-regulated by the treatment in responsive cases.
Conclusions: These results represent the basis for a possible association of ATO with other biological compounds able
to modify the apoptotic pathways, such as inhibitors of the BCL2 family.
Keywords: ATO, Ascorbic acid, Myelodysplastic syndromes, MDS, ApoptosisIntroduction
Arsenic Trioxide (ATO) is an ancient drug that, in the
most recent years, has been rediscovered and evaluated
for the treatment of promyelocytic leukemia, multiple
myeloma, and myelodysplastic syndromes (MDS) [1].
In MDS, two phase-II multicenter trials have reported
interesting results, either in low- or high-risk patients
[2,3], with hematological improvement rates of 20-30%.* Correspondence: sara.galimberti@med.unipi.it
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distribution, and reproduction in any mediumMore recently, arsenic trioxide has been used in com-
bination with thalidomide and retinoic acid in high-risk
MDS patients, resulting in response rate of 48% and effi-
cacy of 25% [4].
ATO exerts its anticancer activity inducing apoptosis
through the disequilibrium of apoptotic/anti-apoptotic
BCL2 family members [5,6] cytochrome C release, loss
of mitochondrial transmembrane potential, reactive oxy-
gen species generation [1], inactivation of NF-kB [7,8],
and activation of caspases [9]. Moreover, an anti-
angiogenetic activity of ATO has also been reported
[10]. Because stable MDS cell lines are still lacking,
PML-RARa-negative acute myeloid leukemia HL60 cellstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Patients' characteristics
Characteristics Patients
No. %
Total patients enrolled 12
Median age, years 69
Sex
Male 7 58
Female 5 42
IPSS risk score
Low 0 0
Intermediate 1 7 59
Intermediate 2 1 8
High 4 33
WPSS risk score
Very low 1 8
Low 3 25
Intermediate 0 0
High 5 42
Very high 3 25
WHO classification
RA 3 25
RARS 0 0
RCMD 0 0
RCMD-RS 0 0
RAEB1 5 42
RAEB2 4 33
Transfusion dependence at baseline
RBC only 8 67
PLT only 1 8
RBC + PLT 1 8
No 2 17
Cytopenias at baseline
0 0 0
1 7 58
2 5 42
3 0 0
Hematological median values at enrollment
N (x109/L) 2,04
Hb (g/dL) 8.9
PLT (x109/L) 174
Karyotype
Normal 5 42
Complex 2 17
+8 1 8
Del7 1 8
Other abnormalities 3 25
RA= refractory anemia, RARS = refractory anemia with ringed sideroblasts,
RCMD= refractory cytopenia with multilineage dysplasia, RCMD-RS = refractory
cytopenia with multilineage dysplasia and ringed sideroblasts, RAEB-
1 = refractory anemia with excess of blasts-1, RAEB-2 = refractory anemia with
excess of blasts-2.
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group reported synergistic effects for the combination of
the proteasome inhibitor Bortezomib and ATO in HL60
cell line [11].
However, the in vivo mechanisms of action of ATO in
MDS patients are still matter of debate. Since ATO
induces apoptosis in vitro, we evaluated the expression
of 93 apoptotic genes in patients’ bone marrow before
and after ATO plus Ascorbic Acid treatment, in the con-
text of the Italian clinical trial NCT00803530, EudracT
Number 2005-001321-28.
In addition, the expression of WT1 and EVI1 has been
evaluated and correlated with those of the apoptotic
genes, because of WT1 and EVI1 prognostic value in
MDS [12,13].
Patients and methods
Patients
Twelve MDS patients receiving ATO plus Ascorbic Acid
in the context of the clinical trial NCT00803530,
EudracT Number 2005-001321-28 were selected for this
molecular characterization. For these patients, RNA col-
lected from the bone marrow immediately before the
first administration of the treatment was available.
ATO was administered at a dosage of 0.3 mg/Kg dur-
ing the first week of therapy, and at a dosage of
0.25 mg/Kg during the subsequent weeks (week 2 to 16);
Ascorbic Acid was administered at 1000 mg IV within
30 minutes after each arsenic trioxide infusion, for 16
consecutive weeks.
Table 1 summarizes patients’ characteristics. Three mL
of bone marrow blood were collected in an EDTA tube
by needle aspiration just before the beginning of the
treatment and after the last administration.
Patients were diagnosed in agreement with WHO cri-
teria and classified according to the International Prog-
nostic Scoring System (IPSS) and the WHO
classification-based prognostic scoring system (WPSS),
as previously described [14,15]. Treatment responses
were assessed according to the International Working
Group (IWG) criteria [16].
This study has been conducted in accordance with the
Declaration of Helsinki, and all patients gave informed
consent for the clinical trial and this molecular
characterization.
Gene expression assays
RNA was extracted from bone marrow blood using
RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). Real-
time PCR quantitative assays for genes involved in apop-
tosis were performed using TaqManW Assays in 384-
Well Microfluidic Cards “TaqManW Human Apoptosis
Array” (Catalog Number 4378701, Applied Biosystems,
CA, USA). Real-time PCR was performed in a 7900HT
Table 2 Results from Quantitative RT-PCR assays in pt
#12 (the test patient)
Gene identification Gene function 2-ΔΔCt
BAK1 Hs00832876_g1 Pro-apoptosis 36.1
BAX Hs00751844_s1 Pro-apoptosis 5.5
BCL2 Hs00608023_m1 Anti-apoptosis 3.2
BIM Hs00708019_s1 Pro-apoptosis 4.4
BCL2L14 Hs00373302_m1 Pro-apoptosis 21.6
BIRC1 Hs01847653_s1 Anti-apoptosis 10.7
BIRC4 Hs00745222_s1 Anti-apoptosis 8.1
BIRC8 Hs01057786_s1 Anti-apoptosis 521.7
BNIP3 Hs00969291_m1 Pro-apoptosis 15.7
BOK Hs00261296_m1 Pro-apoptosis 5.4
CASPASE-5 Hs00362072_m1 Pro-apoptosis 18.2
DEDD2 Hs00370206_m1 Pro-apoptosis 2.8
HRK Hs00705213_s1 Pro-apoptosis 338.8
LTA Hs99999086_m1 Pro-apoptosis 13.1
LTB Hs00242739_m1 Pro-apoptosis 7.1
TNFRSF1A Hs01042313_m1 Pro-apoptosis 3.6
TRAIL Hs00234356_m1 Pro-apoptosis 3.8
TRADD Hs00601065_g1 Pro-apoptosis 3.4
BCL2L10 Hs00368095_m1 Pro-apoptosis 0.32
BIRC5 Hs00977611_g1 Anti-apoptosis 0.41
BIRC7-LIVIN Hs00223384_m1 Anti-apoptosis 0.38
2-ΔΔCt lists how many times a gene is up- or de-regulated in bone marrow
after ATO+ ascorbic acid after treatment versus before therapy.
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were analyzed using SDS 2.2 software.
Quantitative RT-PCR expression of EVI1 gene was
performed as previously described [13]; quantitative
WT1 expression was assessed by using the “WT1 Profi-
leQuantW kit” (Ipsogen, Marseille, France).
Statistical analysis
Gene expression was analyzed using GenespringGx 11.5
(Agilent, Palo Alto, CA, USA). Gene expression values
(Ct) were normalized to the median expression of three
housekeeping genes present in the card (18S, ACTB and
GAPDH). Normalized gene expression (ΔCt) before and
after treatment was compared using two tails paired t-
test. Differential gene expression before and after treat-
ment was calculated (−ΔΔCt) and differences between
patients who experienced a response or not (stable dis-
ease vs major or minor responses) were evaluated by an
unpaired t-test.
Ingenuity pathway analysis was adopted to explore the
interaction between differently expressed genes.
To determine significances in categorized variables,
SPSS 17.0 (SPSS Inc, Chicago, IL, USA) was used to cal-
culate Pearson Chi-square or Fisher’s exact test, when
appropriate. All tests were 2-sided. Results were consid-
ered statistically significant for p ≤ 0.05.
Results
Patients characteristics
Characteristics of patients enrolled in this study are
listed in the Table 1. Note that the purpose of this article
was not the presentation of results arising from the clin-
ical trial; of consequences, the characteristics listed in
the Table are not fully representative of the whole series
of patients.
Three patients were affected by refractory anemia
(RA), 5 by refractory anemia with excess of blasts-1
(RAEB1), and other 4 by refractory anemia with excess
of blasts-2 (RAEB2). IPSS was intermediate-1 in 7 cases,
intermediate-2 in one patient, and high in the remaining
4. Eight patients required red blood cell transfusion, one
only platelet transfusion, and one both red blood cells
and platelets support. The WPSS score was very low in
one case, low in 3, high in 5, and very high in other 3
patients.
Apoptotic genes expression
First, we analyzed the gene expression profile of patient
#12, considered as the “test patient”; indeed, expression
levels of apoptotic and anti-apoptotic genes were ana-
lyzed the day before receiving arsenic trioxide and the
day after the end of the loading phase (at day 6). This
patient, affected by refractory anemia with excess ofblasts-1, with IPSS intermediate-1 risk score, achieved a
major response.
After treatment, 18 genes resulted up-regulated in this
patient (14/18 = 78%, pro-apoptotic), and only 3 genes
down-regulated (2 anti-apoptotic; Table 2).
Among the pro-apoptotic genes, those with higher in-
creasing rate were HRK, BAK1, BCL2L14, and CASPASE-5.
In order to assess if the profile of the “test patient”
could be reproduced in any remaining patients, an un-
supervised clustered analysis was performed. Figure 1
depicts expression levels of assessed genes in the whole
series.
As shown, the “test patient” (lane #6), which was
classified as RAEB1, with IPSS intermediate-1, and
normal karyotype, tightly clustered together with pa-
tient #4 (lane #5), affected by RAEB2, and with pa-
tient #7 (lane #4), affected by RAEB1. These patients
were scored as at high and intermediate-1 IPSS re-
spectively; both showed normal karyotype and high
WT1 levels.
When the gene expression profile was analyzed in the
whole series, in 4 of the 6 cases with stable disease the
gene expression profile did not significantly change (see
patient #2, #7, #10, and #11 in Figure 1).
Figure 1 Unsupervised cluster analysis of apoptotic gene expression modification upon ATO and Ascorbic Acid treatment. Figure
depicts -ΔΔCt of the “test patient” (lane #6) versus the remaining ones.
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apoptotic genes, resulted more frequently up-regulated:
CASPASE-5, CASPASE-14, TNFRSF1A, HRK, BCL2L1,
BCL2L14, TNFSF10, and LTB. On the contrary, BCL2L10
and BIRC8 were the anti-apoptotic genes whose expres-
sion was more frequently increased by ATO and Ascorbic
Acid. In patient #1, who showed an intermediate-1 IPSS,
some genes belonging to the NF-kB pathways (NFKBIA,
NFKBIE, NFKBIZ, RELB) were significantly up-regulated.Two patients achieved a major response: in the patient
with RA the treatment down-regulated 69% of the pro-
apoptotic genes (see case #3 in the Figure 1), whereas
91% of the pro-apoptotic genes were up-regulated in the
patient affected by RAEB1 (case #8).
When gene expression was further analyzed in respect
of response, patients who reached a response (minor or
major) showed a higher induction of BAD than those
with stable disease (Figure 2).
Figure 2 ATO and Ascorbic Acid induced gene expression modification of BAD in patients that reached stable disease or a response
(major or minor).
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strated that ATO plus Ascorbic Acid induced down-
regulation of ICEBERG (p= 0.0075), and up-regulation of
TNFRSF1A (p= 0.0172) and BCL2L14 (p= 0.0384) in
patients’ bone marrow (Figure 3 A, B and C, respectively).
Furthermore, we noticed a basal high expression of
BCL2L10 in two patients affected by RAEB1 and AR,
respectively. In these two patients, treatment induced a
dramatic reduction of BCL2L10 expression. In the
remaining cases, other 4 patients experienced a rele-
vant reduction of BCL2L10 expression, but this reduc-
tion was not significant when the whole series was
evaluated.Pathway analysis
Ingenuity pathway analysis was adopted to explore the
interaction between differently expressed genes. ICEBERG,
TNFRS1A and BCL2L14 were included in the analysis be-
cause they were significantly de-regulated after treatment.Figure 3 Mean and standard deviation of gene expression before and
TNFRSF1A (B) and BCL2L14 (C) in the whole series of patients.BAD was included because of its higher expression in re-
sponder cases. Also BAK1, HRK and BCL2L10 were
included in this analysis because of their increased values
in the “test” sample (Figure 4).Evaluation of expression of WT1 and EVI1 genes
In the present study, we decided to assess if different
values of WT1 and EVI1 measured at diagnosis and after
treatment could be associated with the expression of
several apoptotic genes, with particular interest in a pos-
sible common de-regulation.
At diagnosis, 10 patients showed high levels of WT1;
after therapy, in 4 of them a significant reduction of the
transcript was observed. Interestingly, 3 of them were
the cases that achieved the major response; the correl-
ation between reduction of the WT1 levels and good re-
sponse was significant (p = 0.024).
EVI1 gene expression was detectable at diagnosis in 10
patients, 3 cases with high levels.after ATO and Ascorbic Acid treatment of ICEBERG (A),
Figure 4 Relationships between differentially expressed genes have been explored in the pathway analysis. Up-regulated genes are
reported in red, whereas down-regulated in green.
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tion of the transcript. In the group of patients with low
levels before treatment, only one showed increased levels
(Table 3). No significant correlation between theTable 3 WT1 and EVI1 expression levels before and after
treatment and their correlation with clinical response are
reported
Pt ID WT1 @ start WT1 @ end EVI1 @ start EVI1 @ end response
1 high high low low minor
2 high high low low stable
3 high normal low low major
4 high normal low low stable
5 normal normal high low minor
6 normal normal low low minor
7 high high high low stable
8 high normal low high major
9 high high low low stable
10 high high N/A N/A stable
11 high high high low stable
12 high normal N/A N/A majorbehavior of the EVI1 expression and the quality of re-
sponse, disease progression or death was found.
Moreover, no correlation between expression of WT1
and EVI1 (either measured at diagnosis or after therapy)
and de-regulation of the pro- and anti-apoptotic assessed
genes was observed.Discussion
It is well known that myelodysplastic syndromes are very
heterogeneous entities, characterized by accelerated
rates of apoptosis in early stages and higher prolifera-
tion, accumulation of less differentiated cells, with high
genomic instability in the advanced phases.
Consequently, it is really difficult to derive any conclu-
sive results from the gene expression profiling of few
MDS patients. Moreover, molecular studies performed in
patients receiving ATO that could increase the know-
ledge about real mechanisms of its action are still lack-
ing, thus a homogenously treated series of patients, even
if small, could represent a good opportunity in this field.
Here, we evaluated 12 patients affected by advanced
and resistant MDS receiving ATO and Ascorbic Acid for
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ously observed in vitro by our group also, with particular
interest in the apoptotic pathways.
Thus, we evaluated by quantitative real-time PCR the
expression of 93 genes involved in apoptosis in a “test
patient” (who was analyzed just before and soon after
treatment), and in other 3 patients affected by RA, 4 by
RAEB1, and 4 by RAEB2.
As reported in the result section, in 4 of 6 cases with
stable disease the gene expression profile did not signifi-
cantly change. Two patients achieved a major response:
in the patient with RA the treatment with ATO and As-
corbic Acid down-regulated about 60% of the pro-
apoptotic genes, whereas, in the patient affected by
RAEB, 91% of the pro-apoptotic genes were up-regu-
lated. This observation could have a clinical impact, if we
consider that in the early phases of MDS the goal of
treatment would be the reduction of apoptosis and in-
flammatory status, whereas in the more advanced phases
a perfect drug would exert principally an anti-
proliferative effect.
Another interesting result from the present study is the
demonstration that among principal targets for ATO
there are genes belonging to the BCL2 family, analo-
gously to that already observed in vitro. Interestingly, re-
sponsive patients showed a higher induction of BAD
than those with stable disease. High expression of the
pro-apoptotic BCL2-family proteins (BAK, BAD, BCL-
XS, as well the apoptosis facilitator BCL2L14) has been
previously associated with longer survival and decreased
risk of leukemic transformation [17]. In our series,
BCL2L14 expression was significantly increased by ATO
and Ascorbic Acid, both in the “test patient” and in re-
sponsive cases. On the other hand, the expression of
BCL2L10, an anti-apoptotic gene, resulted significantly
down-regulated in 4 cases, as observed in the “test
patient”.
Moreover, the expression of ICEBERG was significantly
reduced in 8 cases; this gene physiologically inhibits
caspase-1 activity. Caspase-1 is able to activate the IL-1β
precursor; this could be interesting, because various myelo-
suppressive and pro-inflammatory cytokines have been
implicated in the high rates of apoptosis and hematopoietic
suppression seen in MDS [17,18]. Thus, decreased expres-
sion of ICEBERG could be a relevant target for new thera-
peutic strategies in early MDS.
Another gene that was significantly up-regulated after
treatment is the TNFRSFA1 (Tumor necrosis factor re-
ceptor super family member 1A); its protein is one of the
major receptors for the TNFα, and it is physiologically
able to mediate apoptosis [19]. Consequently, its up-
regulation could be another interesting target for treat-
ments in advanced MDS.Finally, a significant association between low WT1 levels
and good response was found, in line with the negative
prognostic role of WT1 in MDS progression previously
shown [20].
Recently, immunological approaches to inactivate
WT1 in acute leukemia and high-risk MDS have been
proposed: these studies provided preliminary evidences
of potential clinical efficacy in these patients [21].
Conclusions
In conclusion, the present study to our knowledge is the
first one that analyzed gene expression profile in a homo-
geneously treated series of MDS patients receiving ATO
plus Ascorbic Acid. It confirmed ex vivo some mechan-
isms of action already demonstrated in vitro. In particular,
genes belonging to the BCL2 family appeared particularly
relevant in the conditioning outcome of MDS patients;
this observation could translate in a possible promising
therapeutic approach with BCL2 inhibitors [22].
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